subject area of
- A Phase I Open-Label Dose-Escalation Study of Intravenous BI 2536 Together With Pemetrexed in Previously Treated Patients With Non–Small-Cell Lung Cancer Academic Article
- A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non–Small-Cell Lung Cancer Academic Article
- A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors Academic Article
- A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy Academic Article
- Adapting the Lung Cancer Symptom Scale(LCSS) to mesothelioma Academic Article
- Butein impairs the protumorigenic activity of malignant pleural mesothelioma cells Academic Article
- Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy Academic Article
- HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome Academic Article
- Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Academic Article
- Malignant Pleural Mesothelioma Academic Article
- Multitargeted Antifolate LY231514 as First-Line Chemotherapy for Patients With Advanced Non–Small-Cell Lung Cancer: A Phase II Study Academic Article
- Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy Academic Article
- Pemetrexed safety and dosing strategy Academic Article
- Phase I Clinical and Pharmacokinetic Study of Pemetrexed and Carboplatin in Patients With Malignant Pleural Mesothelioma Academic Article
- Phase I Open-Label Study of Continuous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Non-Small Cell Lung Cancer Patients Academic Article
- Phase I/II Study of Pemetrexed With or Without ABT-751 in Advanced or Metastatic Non–Small-Cell Lung Cancer Academic Article
- Phase II Study of Concurrent Pemetrexed, Cisplatin, and Radiation Therapy for Stage IIIA/B Unresectable Non–Small Cell Lung Cancer Academic Article
- Phase II Study of Pemetrexed With and Without Folic Acid and Vitamin B12as Front-Line Therapy in Malignant Pleural Mesothelioma Academic Article
- Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma Academic Article
- Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma Academic Article
- Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma Academic Article
- SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells Academic Article
- Synergistic Antitumor Effects of Regulatory T Cell Blockade Combined with Pemetrexed in Murine Malignant Mesothelioma Academic Article
- The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review Academic Article
- The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. Academic Article
- Trimodality Therapy With Induction Chemotherapy Followed by Extrapleural Pneumonectomy and Adjuvant High-Dose Hemithoracic Radiation for Malignant Pleural Mesothelioma Academic Article